| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -73.3 | -43.8 |
| Net income | -73.3 | -43.8 |
| EPS (diluted, $ a share) | $-1.33 | $-0.92 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CELC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Celcuity Inc.: key numbers
- Share price
- $60.57Close, Nov 16
- Market cap
- $2.98B
- Shares outstanding
- 49.13MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Celcuity Inc.
All →Celcuity Financial Results
Celcuity Inc. reported financial results for the third quarter of 2026, highlighting the commercial launch of REVTORPYK (gedatolisib) on September 30, 2026. The company reported that 91% of U.S. commercial and Medicare lives are covered by health plans for the new treatment, with 78% of top strategic accounts already prescribing the drug.
- Term
- Q3 2026
“Our commercial and medical affairs teams have laid the foundation for a strong launch over the past few years, and their efforts are paying off. Physicians are enthusiastic and eager to treat their patients with REVTORPYK, and we are pleased with their interest in getting eligible patients on treatment in the initial weeks since we launched.”
Brian Sullivan, CEO and co-founder of Celcuity
Celcuity Leadership Change
Celcuity Inc. has appointed David W. Gryska to its Board of Directors, effective October 1, 2026, increasing the board size to nine members. Mr. Gryska, a former CFO of Incyte and Celgene, will also serve on the Audit and Compensation Committees. His appointment comes as the company transitions to a commercial-stage entity following its first FDA approval for REVTORPYK.
- Counterparty
- David W. Gryska
Celcuity Product Launch
Celcuity Inc. announced the commercial availability of REVTORPYK™ (gedatolisib) in the United States for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation. The therapy, which was FDA-approved in July 2026, is the first to inhibit all class I PI3K isoforms and mTOR complexes to blockade the PAM pathway. The company has also launched the REVTORPYK Support Services program to assist with patient access and financial assistance.